Inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase
View/ Open
File version
Version of Record (VoR)
Author(s)
Schoenen, Frank J.
Weiner, Warren S.
Baillargeon, Pierre
Brown, Chris
Chase, Peter
Ferguson, Jill
Fernandez-Vega, Virneliz
Ghosh, Partha
Hodder, Peter
Krise, Jeffrey P.
Matharu, Daljit S.
Neuenswander, Benjamin
Porubsky, Patrick
Rogers, Steven
Skinner-Adams, Tina
Sosa, Melinda
Spicer, Timothy
To, Joyce
Tower, Nichole A.
Trenholme, Katharine R.
Wang, Jenna
Whipple, David
Aubé, Jeffrey
Rosen, Hugh
Lucile White, E.
Dalton, John P.
Gardiner, Donald L.
Year published
2013
Metadata
Show full item recordAbstract
Malaria is one of the most prevalent human parasitic diseases and is a global health issue accounting for >600,000 deaths annually. For survival, the Plasmodium falciparum (Pf) malaria parasite requires the action of a number of metallo-aminopeptidases that each display restricted amino acid specificities, including PfM1MAA (membrane alanine aminopeptidase), PfM17LAP (leucine aminopeptidase), and PfM18AAP (aspartyl aminopeptidase), which are thought to act in concert to degrade host erythrocyte hemoglobin that the parasite uses as a source of amino acid building blocks for the synthesis of its own proteins. Since there are ...
View more >Malaria is one of the most prevalent human parasitic diseases and is a global health issue accounting for >600,000 deaths annually. For survival, the Plasmodium falciparum (Pf) malaria parasite requires the action of a number of metallo-aminopeptidases that each display restricted amino acid specificities, including PfM1MAA (membrane alanine aminopeptidase), PfM17LAP (leucine aminopeptidase), and PfM18AAP (aspartyl aminopeptidase), which are thought to act in concert to degrade host erythrocyte hemoglobin that the parasite uses as a source of amino acid building blocks for the synthesis of its own proteins. Since there are several small molecule inhibitors of PfM1MAA and PfM17LAP, and very few small molecule inhibitors of PfM18AAP, we set out to identify small molecule inhibitors of PfM18AAP. Biochemical assays employing rPfM18AAP, native PfM18AAP, recombinant Fasciola hepatica cathepsin L1 (rFhCTSL1), rPfM1MAA, rPfM17LAP, and rhM18, and cell-based parasite growth inhibition and cytotoxicity assays were used to identify CID23724194 (from the NIH MLSMR) as a viable starting point for medicinal chemistry optimization. Two rounds of structure-activity relationship studies were performed to generate the probe ML369 (CID56846691). The probe is the best-in-class small molecule inhibitor of PfM18AAP; however, certain liabilities discussed in detail in the probe report limit its usefulness. When the probe is used as recommended, the probe is "fit-for-purpose" and should be useful for advancing the field
View less >
View more >Malaria is one of the most prevalent human parasitic diseases and is a global health issue accounting for >600,000 deaths annually. For survival, the Plasmodium falciparum (Pf) malaria parasite requires the action of a number of metallo-aminopeptidases that each display restricted amino acid specificities, including PfM1MAA (membrane alanine aminopeptidase), PfM17LAP (leucine aminopeptidase), and PfM18AAP (aspartyl aminopeptidase), which are thought to act in concert to degrade host erythrocyte hemoglobin that the parasite uses as a source of amino acid building blocks for the synthesis of its own proteins. Since there are several small molecule inhibitors of PfM1MAA and PfM17LAP, and very few small molecule inhibitors of PfM18AAP, we set out to identify small molecule inhibitors of PfM18AAP. Biochemical assays employing rPfM18AAP, native PfM18AAP, recombinant Fasciola hepatica cathepsin L1 (rFhCTSL1), rPfM1MAA, rPfM17LAP, and rhM18, and cell-based parasite growth inhibition and cytotoxicity assays were used to identify CID23724194 (from the NIH MLSMR) as a viable starting point for medicinal chemistry optimization. Two rounds of structure-activity relationship studies were performed to generate the probe ML369 (CID56846691). The probe is the best-in-class small molecule inhibitor of PfM18AAP; however, certain liabilities discussed in detail in the probe report limit its usefulness. When the probe is used as recommended, the probe is "fit-for-purpose" and should be useful for advancing the field
View less >
Publisher URI
Copyright Statement
© 2013 National Center for Biotechnology Information (NCBI). The attached file is reproduced here in accordance with the copyright policy of the publisher. Please refer to the journal's website for access to the definitive, published version.
Subject
Medical Parasitology